Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Erasca Inc ERAS
$18.15
▼ -2.84%
($-0.53)
🗓️ Earnings Next Week
Open
$18.73
Prev Close
$18.68
Day Range
$17.77 – $18.92
52W Range
$1.33 – $24.28
Market Cap
$6.30B
Beta
0.67
EPS (TTM)
$-0.93
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-15 |
| Shares Out. | 342,240,000 |
| Website | erasca.com/ ↗ |
| Phone | 18584656511 |
| Employees | 103 |
| Net Income | -$183.4M |
| Free Cash Flow | -$91.4M |
| Total Assets | $461.2M |
| Total Liabilities | $67.7M |
| Equity | $393.5M |
About Erasca Inc
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Erasca Inc is a publicly traded company under the ticker symbol ERAS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)